Release Date: March 31, 2025
Expiration Date: March 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, these experts provide evidence-based strategies for managing unresectable and metastatic NSCLC. Through case-based learning, participants explore key clinical trials, molecular testing applications, and treatment sequencing with the aim of enhancing clinical decision-making and improving outcomes for patients with advanced NSCLC.
This educational activity is an archive of the live symposium held on February 22, 2025.
Target Audience
This educational activity is directed toward medical oncologists, pathologists, molecular pathologists, and thoracic surgeons.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review evidence-based approaches to managing unresectable NSCLC, including the integration of immunotherapy and targeted therapies in unresectable settings
- Analyze findings from key trials to assess the potential impact of novel therapies and combinations on clinical outcomes in unresectable and metastatic NSCLC
- Discuss the role of molecular profiling in guiding treatment for EGFR-mutant NSCLC and strategies to address resistance mechanisms such as MET amplification and HER3 overexpression
- Explore patient selection, therapy sequencing, and the management of adverse events to optimize individualized care for patients with EGFR-mutant or immunotherapy-eligible NSCLC
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
The University of Chicago Medical Center
Chicago, IL
Disclosures: Grant/Research Support: AIFA, AIRC, Horizon 2020, Italian Ministry of Health, TRANSCAN; Other: Personal Financial Interests: AbbVie, American Society for Radiation Oncology, Aptitude Health, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IDEOlogy Health, International Association for the Study of Lung Cancer, IO Biotech, Janssen Pharmaceuticals, Merck, Mirati Therapeutics, Natera, Novocure, Nuvation Bio, OncoHost, Pfizer, Regeneron, Revolution Medicines, Roche, Takeda
Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine
Associate Director, Medical Oncology-Hematology Fellowship Program
Co-Director, Center for Thoracic Cancers
Chief, Thoracic Oncology
Yale School of Medicine
New Haven, CT
Disclosures: Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Mirati; Consultant/Honoraria Recipient: AstraZeneca, Bayer, Daiichi Sankyo, Janssen, Lilly, Merck, Regeneron, Summit Therapeutics
Biagio Ricciuti, MD, PhD
Thoracic Medical Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Advisory Board: AstraZeneca, Amgen, Bristol Myers Squibb, Regeneron
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
